AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17685870 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic drug administration (protein kinase C inhibitors and somatostatin analogs)
Number of subjects: 0
Study 17685870 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal delivery of local therapies
Number of subjects: 0
Study 15573392 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirotel portable spirometer
Number of subjects: 59
Study 15573392 — intervention group
Group type: COMPARATOR
Intervention: Laboratory spirometer (Jeager PFT)
Number of subjects: 59
Study 15573392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both spirometers
Number of subjects: 59
Study 12066727 — intervention group
Group type: COMPARATOR
Intervention: 0.5% lidocaine solution 3 mg kg(‐1) (n=20)
Number of subjects: 42
Study 12066727 — intervention group
Group type: EXPERIMENTAL
Intervention: mepivacaine 5 mg kg(‐1) (n=22)
Number of subjects: 42
Study 12066727 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 3 mg kg(‐1) (n=20)
Number of subjects: 42
Study 10718563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense interval training (10 x 400 m at 5.94+/‐0.19 m x s(‐1) with recovery of 60, 120 or 180 s)
Number of subjects: 7
Study 10718563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense interval training
Number of subjects: 7
Study 8872694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glycopyrrolate
Number of subjects: 37
Study 8872694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular glycopyrrolate
Number of subjects: 37
Study 8872694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 8872694 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glycopyrrolate
Number of subjects: 37
Study 1640303 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 47
Study 1640303 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic treatment)
Number of subjects: 47
Study 6430690 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB)
Number of subjects: 40
Study 6430690 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (DPH)
Number of subjects: 40
Study 31414980 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet therapy with <5 g long chain triglyceride fat per day recommended by dietitians in Australia/New Zealand, UK, and Ireland
Number of subjects: 64
Study 31414980 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet therapy duration of 4 weeks or 6 weeks
Number of subjects: 64
Study 30241511 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-monitoring (TM)
Number of subjects: 50
Study 30241511 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital monitoring (HM)
Number of subjects: 50
Study 28577680 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 87.5 mg bid
Number of subjects: 36
Study 28577680 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil (various doses: 37.5, 87.5, 125 mg daily, 37.5 and 87.5 mg bid)
Number of subjects: 36
Study 28577680 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (exercise testing only)
Number of subjects: 36
Study 23954983 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-management intervention (SMI)
Number of subjects: 174
Study 23954983 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (CG)
Number of subjects: 174
Study 24127442 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 472
Study 24127442 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (no GO)
Number of subjects: 472
Study 20852004 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg once daily
Number of subjects: 0
Study 20852004 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 0
Study 20852004 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (both doses)
Number of subjects: 0
Study 18501865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood and Feelings Questionnaire, short form (MFQ‐SF)
Number of subjects: 1375
Study 18501865 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Anxiety Sensitivity Index (ASI)
Number of subjects: 1375
Study 17006117 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2% wt/vol oral rinse
Number of subjects: 14
Study 17006117 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine 0.15% wt/vol oral rinse
Number of subjects: 14
Study 14602795 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant GH (5 micro g/kg.d)
Number of subjects: 12
Study 14602795 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 12
Study 14602795 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 12
Study 14602795 — intervention group
Group type: COMPARATOR
Intervention: GH receptor antagonism
Number of subjects: 12
Study 10765074 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal power Doppler sonography (TRPDS) measuring resistive index (RI)
Number of subjects: 140
Study 9303669 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive distribution of informative leaflets on NSAIDs
Number of subjects: 348
Study 9303669 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 348
Study 8222304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional adrenaline and heater probe
Number of subjects: 100
Study 8222304 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 2946507 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg b.i.d.
Number of subjects: 24
Study 2946507 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 20 mg b.i.d.
Number of subjects: 24
Study 2946507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29320770 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1255
Study 29320770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular disease
Number of subjects: 1255
Study 29320770 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral vascular disease
Number of subjects: 1255
Study 29320770 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hemoglobin A1c (HbA1c)
Number of subjects: 1255
Study 29320770 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of self-dependency
Number of subjects: 1255
Study 29320770 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher albumin
Number of subjects: 1255
Study 29320770 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 1255
Study 25916256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain expectation
Number of subjects: 0
Study 25916256 — intervention group
Group type: EXPERIMENTAL
Intervention: Average pain intensity
Number of subjects: 0
Study 25916256 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe pain intensity
Number of subjects: 0
Study 25916256 — intervention group
Group type: EXPERIMENTAL
Intervention: High composite pain index
Number of subjects: 0
Study 25916256 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with pain level
Number of subjects: 0
Study 24588644 — intervention group
Group type: EXPERIMENTAL
Intervention: PTEN protein
Number of subjects: 0
Study 24588644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ci‐VSP
Number of subjects: 0
Study 23776123 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal weight gain (NWG)
Number of subjects: 13840
Study 23776123 — intervention group
Group type: EXPERIMENTAL
Intervention: Head circumference gain (HCG)
Number of subjects: 13840
Study 20230914 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones 200mg daily
Number of subjects: 283
Study 20230914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 19102123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic acoustic neural stimulus (customized to each patient's audiometric profile)
Number of subjects: 470
Study 16911937 — intervention group
Group type: EXPERIMENTAL
Intervention: DDS implantation through the portal vein (P-implanted group)
Number of subjects: 190
Study 16911937 — intervention group
Group type: EXPERIMENTAL
Intervention: DDS implantation through the hepatic artery (A-implanted group)
Number of subjects: 190
Study 16911937 — intervention group
Group type: EXPERIMENTAL
Intervention: DDS implantation through both the hepatic artery and portal vein (A+P-implanted group)
Number of subjects: 190
Study 16911937 — intervention group
Group type: COMPARATOR
Intervention: Control group (subgroup b)
Number of subjects: 190
Study 16911937 — intervention group
Group type: COMPARATOR
Intervention: Control group (subgroup c)
Number of subjects: 190
Study 12878791 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent treatment protocol (surgery, craniospinal irradiation, 4 courses of chemotherapy including VCR, VP, CBDCA, CTX, IF, CDDP, followed by 8 courses of maintenance chemotherapy with VCR, CDDP, CCNU)
Number of subjects: 77
Study 12878791 — intervention group
Group type: COMPARATOR
Intervention: Earlier treatment protocol (surgery and radiotherapy followed by chemotherapy)
Number of subjects: 77
Study 12878791 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent treatment protocol for high-risk patients
Number of subjects: 77
Study 12878791 — intervention group
Group type: COMPARATOR
Intervention: Earlier treatment protocol for high-risk patients
Number of subjects: 77
Study 11049140 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise treatment
Number of subjects: 0
Study 11049140 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9004971 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Reach (FR)
Number of subjects: 28
Study 9004971 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Leg Stance (SLS)
Number of subjects: 28
Study 7875183 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ibopamine (IBO)
Number of subjects: 32
Study 7875183 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide mononitrate (ISMN)
Number of subjects: 32
Study 7875183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IBO and ISMN
Number of subjects: 32
Study 7875183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2831248 — intervention group
Group type: EXPERIMENTAL
Intervention: Test diet (1660 mg phosphorus, 420 mg calcium)
Number of subjects: 16
Study 2831248 — intervention group
Group type: COMPARATOR
Intervention: Control diet (820 mg calcium, 930 mg phosphorus)
Number of subjects: 16
Study 30571419 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task balance/mobility training
Number of subjects: 84
Study 30571419 — intervention group
Group type: COMPARATOR
Intervention: Single-task balance/mobility group
Number of subjects: 84
Study 30571419 — intervention group
Group type: COMPARATOR
Intervention: Upper-limb exercise (control)
Number of subjects: 84
Study 28981760 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of possible serious bacterial infection (PSBI) for newborns at health posts by Health Extension Workers (HEWs) with additional equipment, support, and supervision.
Number of subjects: 0
Study 28981760 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving improved implementation of the Health Extension Programme without additional PSBI management.
Number of subjects: 0
Study 28981760 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving PSBI management.
Number of subjects: 0
Study 28981760 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group costs.
Number of subjects: 0
Study 28981760 — intervention group
Group type: COMPARATOR
Intervention: Control group costs.
Number of subjects: 0
Study 28981760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of the intervention.
Number of subjects: 0
Study 28073387 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 149
Study 28073387 — intervention group
Group type: EXPERIMENTAL
Intervention: No surgery
Number of subjects: 149
Study 28073387 — intervention group
Group type: COMPARATOR
Intervention: Control (age-matched children without recurrent acute otitis media)
Number of subjects: 149
Study 23969321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh kimchi (1‐day‐old)
Number of subjects: 21
Study 23969321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented kimchi (10‐day‐old)
Number of subjects: 21
Study 21839609 — intervention group
Group type: EXPERIMENTAL
Intervention: Microincision with continuous mode
Number of subjects: 180
Study 21839609 — intervention group
Group type: EXPERIMENTAL
Intervention: Microincision with pulse mode
Number of subjects: 180
Study 21839609 — intervention group
Group type: EXPERIMENTAL
Intervention: Microincision with burst mode
Number of subjects: 180
Study 21839609 — intervention group
Group type: COMPARATOR
Intervention: Small-incision coaxial phacoemulsification
Number of subjects: 180
Study 19593941 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gram of fish oil daily for 6 months (containing 180 mg eicosapentaenoic acid and 120 mg docosahexaenoic acid)
Number of subjects: 120
Study 19593941 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 120
Study 17415202 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral infarction
Number of subjects: 3567
Study 17415202 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cerebral infarction)
Number of subjects: 3567
Study 15136062 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (6g per day)
Number of subjects: 29
Study 15136062 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 29
Study 11394697 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno‐venous hemodiafiltration (CVVHDF)
Number of subjects: 88
Study 11394697 — intervention group
Group type: COMPARATOR
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 88
Study 10193230 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA patch
Number of subjects: 180
Study 10193230 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch with infiltration analgesia (2 ml lignocaine 2% with adrenaline)
Number of subjects: 180
Study 10193230 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 180
Study 7602741 — intervention group
Group type: EXPERIMENTAL
Intervention: Binkhorst formula
Number of subjects: 887
Study 7602741 — intervention group
Group type: COMPARATOR
Intervention: SRK Linear Regression formula
Number of subjects: 887
Study 2403736 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 354512 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomycin combined with Eleutherococcus (1st group)
Number of subjects: 100
Study 354512 — intervention group
Group type: COMPARATOR
Intervention: Monomycin alone (2nd group)
Number of subjects: 100
Study 31704437 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, progressive treadmill walking exercise (TMWX) training 3 times/week for 12 weeks, progressing from 15-min light-to-moderate intensity to 40-min vigorous intensity
Number of subjects: 88
Study 31704437 — intervention group
Group type: COMPARATOR
Intervention: Supervised, minimal intensity, stretching-and-resistance exercise
Number of subjects: 88
Study 28719555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 76
Study 26317258 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous local wound infusion treatment in addition to WHO standard pain management protocol (Group 1)
Number of subjects: 42
Study 26317258 — intervention group
Group type: COMPARATOR
Intervention: WHO standard pain management protocol (Group 2)
Number of subjects: 42
Study 26317258 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous local wound infusion treatment (Group 1)
Number of subjects: 42
Study 22476165 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS) - 3 sets of 30-second stretches of the hamstrings, quadriceps, hip flexors, and piriformis.
Number of subjects: 13
Study 22476165 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI) - visualization of motor activities conducted by a trained technician.
Number of subjects: 13
Study 22476165 — intervention group
Group type: COMPARATOR
Intervention: Quiet Rest (QR) - control condition with no specific intervention.
Number of subjects: 13
Study 21398011 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tranexamic acid in normal saline solution
Number of subjects: 40
Study 21398011 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 40
Study 18450903 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free powder lidocaine delivery system (0.5 mg of lidocaine)
Number of subjects: 579
Study 18450903 — intervention group
Group type: COMPARATOR
Intervention: Sham placebo system
Number of subjects: 579
Study 16525601 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinzhi Hanshuye
Number of subjects: 30
Study 16525601 — intervention group
Group type: COMPARATOR
Intervention: Control (tosylchloramide sodium and calcium hydroxide)
Number of subjects: 30
Study 14612482 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 100
Study 14612482 — intervention group
Group type: COMPARATOR
Intervention: Parenteral opioids
Number of subjects: 100
Study 14612482 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia
Number of subjects: 100
Study 10756406 — intervention group
Group type: EXPERIMENTAL
Intervention: Febrile convulsion (FC) group
Number of subjects: 103
Study 10756406 — intervention group
Group type: COMPARATOR
Intervention: Control group (CC)
Number of subjects: 103
Study 1723217 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 47
Study 1723217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 7343379 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol RETARD 100 mg
Number of subjects: 40
Study 7343379 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol RETARD 200 mg
Number of subjects: 40
Study 31066887 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 60
Study 31066887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29892933 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-100 (15 g/day)
Number of subjects: 40
Study 29892933 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 27462894 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Intermittent Pressure Group
Number of subjects: 38
Study 27462894 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric Incentive Spirometer Group
Number of subjects: 38
Study 27462894 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Positive Intermittent Pressure and Volumetric Incentive Spirometer)
Number of subjects: 38
Study 24268631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontapered PICC
Number of subjects: 332
Study 24268631 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse tapered PICC
Number of subjects: 332
Study 24268631 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cancer
Number of subjects: 332
Study 24268631 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 332
Study 22102633 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg allopurinol (with an interval of 12 h) starting within 4 h after birth
Number of subjects: 54
Study 22102633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no allopurinol treatment)
Number of subjects: 54
Study 20429491 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics treatment for trichomoniasis (365 women, 83%)
Number of subjects: 2428
Study 20429491 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment for trichomoniasis (63 women, 15%)
Number of subjects: 2428
Study 20429491 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without trichomoniasis)
Number of subjects: 2428
Study 17047001 — intervention group
Group type: COMPARATOR
Intervention: TEC (docetaxel 75 mg/m2, epirubicin 75 mg/m2, cyclophosphamide 500 mg/m2) every 3 weeks
Number of subjects: 99
Study 17047001 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐‐>T (E 100 mg/m2, C 600 mg/m2 x 4, then T 100 mg/m2 x 4) every 2 weeks
Number of subjects: 99
Study 17047001 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐‐>EC (T 100 mg/m2 x 4, then E 100 mg/m2, C 600 mg/m2 x 4) every 2 weeks
Number of subjects: 99
Study 15758908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention in the Polyp Prevention Trial
Number of subjects: 2079
Study 15758908 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete removal or missed cancer
Number of subjects: 2079
Study 15526544 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiruline
Number of subjects: 24
Study 15526544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10194726 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar attachments
Number of subjects: 36
Study 10194726 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnet attachments
Number of subjects: 36
Study 10194726 — intervention group
Group type: COMPARATOR
Intervention: Ball attachments
Number of subjects: 36
Study 10194726 — intervention group
Group type: COMPARATOR
Intervention: Straight bars (reference group)
Number of subjects: 36
Study 7773814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon defect closed (group I)
Number of subjects: 50
Study 7773814 — intervention group
Group type: COMPARATOR
Intervention: Tendon defect left open (group II)
Number of subjects: 50
Study 2227588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 every 28 days
Number of subjects: 57
Study 2227588 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin 400 mg/m2 every 28 days
Number of subjects: 57
Study 2227588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin second-line treatment
Number of subjects: 57
Study 2227588 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin second-line treatment
Number of subjects: 57
Study 7126440 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0
Study 7126440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31178170 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented group
Number of subjects: 92